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ABSTRACT 
Background: Type 2 diabetes mellitus (T2DM) and Nonalcoholic fatty liver disease (NAFLD) have risen globally 
to epidemic proportions. The study was aimed to determine the prevalence of NAFLD and its association with 
cardio-metabolic risk factors in T2DM subjects. Method: In a case control study, 212 consecutive, T2DM subjects 
with age ≥ 30 years, were evaluated from December 2017 to December 2018 at Mahatma Gandhi Medical College 
&Hospital, Jaipur, Rajasthan. Subjects with history of significant alcohol consumption, evidence of cirrhosis, 
hepatotoxic drugs, and other known causes of fatty liver were excluded. The T2DM subjects were divided into (1) 
NAFLD - patients with USG evidence of fatty changes in the liver (2) Non-NAFLD – patients without any USG 
evidence of fatty changes in the liver. Coronary artery disease was screened by any past medical history of CAD or 
electrocardiographic or angiography evaluation. Continuous variables were expressed as mean with standard 
deviation. Comparison of continuous data between subgroups was done by using Independent student’s t-test or 
Mann Whitney U test. All statistical analysis was carried out by SPSS version 25. Result:55.66% diabetics had 
comorbid NAFLD. Both study groups had comparable mean age (p 0.719) and gender distribution (p 0.482). 
Subjects with NAFLD had significantly higher BMI (p 0.0001), mean waist circumference (p <0.001), waist hip 
ratio (p <0.001), systolic BP (p 0.001), diastolic BP (p 0.024), HbA1c (p 0.021), total cholesterol (p 0.0426) & 
triglyceride (p 0.02). Mean LDL (p 0.054), VLDL (p 0.235) & HDL (p 0.113) values were comparable in two study 
groups, suggesting no significant association with NAFLD. 32 (15.09%) subjects had coronary artery disease 
(CAD). Diabetics with NAFLD had significantly higher CAD (22.03% vs 9.57%, p 0.02).Conclusion: Diabetics 
with NAFLD had significantly higher cardio-metabolic risk factors, leading to increased associated risk of CAD. 
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. 
INTRODUCTION  
Non-alcoholic fatty liver disease (NAFLD) is a 
disorder characterized by fat accumulation in the liver 
which is closely associated with insulin resistance and 
Type 2 diabetes (T2DM). [1-3]  
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NAFLD is a spectrum of liver disease that 
encompasses simple fatty infiltration in >5% of 
hepatocytes (steatosis), fatty infiltration plus 
inflammation (Nonalcoholic steatohepatitis), fibrosis 
and ultimately cirrhosis, in the absence of excessive 
alcohol consumption (a threshold of <20 g/day for 
women and <30 g/day for men). [4] The prevalence of 
NAFLD has been reported as 15-20% in general 
population & 50–87.1% in Type 2 Diabetics.[5-8] 
Adoption of a sedentary lifestyle and globalization of 
Western diet is associated with an increase in the 
prevalence of NAFLD in developing nations. In many 
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parts of the world NAFLD has become the 
predominant cause of chronic liver disease and 
subsequently for liver transplantation. [9]It is estimated 
that by the year 2025, three-quarters of the world’s 
diabetics will be in non-industrialized countries and 
almost a third in India and China alone. [10] Already 
4.3–13.9% of the urban and 2.7–3.7% of the rural 
Indian population are diabetic. [11, 12]The high 
prevalence of NAFLD in Western countries is probably 
due to the contemporary epidemic of obesity and 
associated metabolic complication. Obesity, Type 2 
diabetes, and hyperlipidemia are recognized as risk 
factors for NAFLD. Accumulating evidence suggests 
that NAFLD can be regarded as part of or, indeed a 
hepatic manifestation of metabolic syndrome. Also, 
NAFLD as a syndrome is an optimal biological milieu 
in which T2DM can develop. NAFLD influence the 
severity of hepatic insulin resistance and may precede 
development of Type-2 diabetes and cardiovascular 
disease.[13,14]NAFLD has been associated with markers 
of subclinical atherosclerosis (such as impaired flow-
mediated vasodilatation), endothelial dysfunction, 
increased arterial stiffness and carotid artery intima–
media thickness.[15] By present trends, India has been 
predicted to face an epidemic of T2DM & NAFLD in 
near future, which makes it pertinent to study 
association of both these disorders. It remains 
important to define cardio-metabolic factors which are 
associated with the presence of NAFLD in Indian 
diabetic patients.  
 
MATERIAL AND METHOD 
 
In a case control study, 212 consecutive, Type 2 
diabetes mellitus (American Diabetes Association 
ADA criteria, presenting in OPD or IPD at Department 
of Medicine, Mahatma Gandhi Medical College 
&Hospital, Jaipur from December 2017 to December 
2018 subjects were evaluated. T2DM subjects with age 
≥ 30 years were evaluated. Subjects with history of 
significant alcohol consumption were excluded 
(significant alcohol consumption be defined as >21 
standard drinks per week in men and >14 standard 
drinks per week in women in previous 2 year period). 
A standard alcoholic drink defined as any drink that 
contains about 14 g of pure alcohol. Subjects with 
history or evidence of cirrhosis, hepatotoxic drugs, 
drugs known to cause fatty liver and other known cause 
of liver disease by following etiologies- Hepatitis B & 
C (HbsAg/Anti HCV antibody), Autoimmune (ANA) 
were excluded. We also excluded subjects with 
cirrhosis, other known causes of fatty liver (history of 
rapid weight loss, starvation, surgical procedures- 
biliopancreatic diversion, extensive small bowel 
resection, jejunoileal bypass, inflammatory bowel 
disease) and subjects with significant unstable physical 
illness (eg. Acute myocardial infarction, Diabetic 
ketoacidosis, Hyperglycemic hyperosmolar coma).  
NAFLD was further classified based on standard 
ultrasonographic imaging criteria as: Grade I (Mild 
Steatosis) - increased echogenicity of the liver along 
with visible periportal and diaphragmatic echogenicity; 
Grade II (Moderate Steatosis) - increased echogenicity 
of the liver along with invisible periportal 
echogenicity, without diaphragmatic fading and Grade 
III (Severe Steatosis) - increased echogenicity of the 
liver along with invisible periportal echogenicity, with 
diaphragmatic fading. Further, the T2DM patient study 
group was divided into 2 subgroups: NAFLD - patients 
with USG evidence of fatty changes in the liver 
(Cases). Non-NAFLD – patients without any USG 
evidence of fatty changes in the liver (Controls).  
Detailed physical examination was carried out with 
emphasis on blood pressure, height, weight, and waist-
hip ratio. Laboratory investigations included 
HbA1c, lipid profile (total cholesterol, LDL, HDL, 
VLDL, and triglycerides) and liver function tests. 
BMI was calculated by dividing weight in kilograms 
by height in meters squared. Waist circumference was 
measured at the level of the umbilicus. Coronary artery 
disease (CAD) was screened by any past medical 
history of CAD or electrocardiographic or angiography 
evaluation. Continuous variables were expressed as 
mean with standard deviation (S.D.). Comparison of 
continuous data between subgroups was done by using 
Independent student’s t-test or Mann Whitney U test. 
All statistical analysis was carried out by SPSS version 
25[Table 1,Figure 1].The study was approved by the 
institutional ethics committee.  
 
RESULTS 
 
Among 212 T2DM subjects studied, approximately 
half of the studied diabetics had comorbid NAFLD 
(55.66%, 118). The mean age in T2DM subjects with 
NAFLD was 57.59±11.22 years; as compared to 
57.14±11.19 years in subjects without NAFLD (p 
0.719). Both study groups had comparable gender 
distribution (p 0.482). Subjects with NAFLD had 
significantly higher mean BMI (34.59±4.83) as 
compared to subjects without NAFLD (25.73±2.92). 
The difference was statistically significant (p 
0.0001).In diabetic subjects with NAFLD mean waist 
circumference was significantly higher (91.6 ±4.83 cm) 
as compared to DM (85.6±7.61 cm) group. (p <0.001). 
The mean waist hip ratio of T2DM subjects with 
NAFLD was significantly higher than subjects with 
NAFLD (p <0.001). The mean systolic BP in subjects 
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with NAFLD was 127.49±23.82 mmHg as compared to 
115.14±18.14 mmHg in subjects without NAFLD. This 
difference was significant (p 0.001). The mean 
diastolic BP in T2DM subjects with NAFLD was 
79.04±11.37 mmHg as compared to 75.42±10.93 
mmHg in subjects without NAFLD. This difference 
was significant (p 0.024). The mean HbA1c in diabetic 
subjects with NAFLD was higher (7.07±1.96), as 
compared to diabetics without NAFLD (6.02±1.74). 
The difference was statistically significant (p 0.021). 
Total cholesterol (p 0.0426) & triglyceride (p 0.02) 
levels were significantly higher in T2DM subjects with 
NAFLD as compared to T2DM subjects without 
NAFLD. Mean LDL (p 0.054), VLDL (p 0.235) & 
HDL (p 0.113) values were comparable in two study 
groups, suggesting no significant association with 
NAFLD. 32 (15.09%) subjects had coronary artery 
disease, including 22.03% of diabetics with NAFLD 
and 9.57% without comorbid NAFLD (p 0.02). 
 
Table 1: Comparison of characteristics of Type 2 Diabetes mellitus patients with and without NAFLD 
 
Variable DM+NAFLD(n 118) DM(n 94) P value 
Age (Years) 57.59±11.22 57.14±11.19 0.719 
Sex (% Males) 57.63 62.77 0.482 
BMI (Kg/m2) 34.59±4.83 25.73±2.92 0.0001 
Waist Circumference (in cm) 91.6 ±4.83 85.6±7.61 < 0.001 
Waist hip ratio 0.96±0.02 0.87±0.09 <0.001 
Systolic BP (mmHg) 127.49±23.82 115.14±18.14 0.001 
Diastolic BP (mmHg) 79.04±11.37 75.42±10.93 0.024 
HbA1c 7.07±1.96 6.02±1.74 0.021 
Total Cholesterol (mg/dl) 217.3±19.42 193.66±17.90 0.043 
TG (mg/dl) 133.56±20.23 109.00±21.32 0.02 
HDL (mg/dl) 44.55±14.82 47.65±13.25 0.113 
LDL(mg/dl) 122.80±25.53 116.10±24.35 0.0540 
VLDL (mg/dl) 27.96±11.49 29.90±12.26 0.235 
values are mean ± SD 
 
Figure 1: Prevalence of CAD in diabetics with NAFLD 
 
 
DISCUSSION 
Among the 212 T2DM subjects studied, 55.66% (118) 
had NAFLD. Kalra S et al (2013) in SPRINT study in 
189 Indian centers, evaluated 924 T2DM subjects, 
identified 56.5% subjects to have NAFLD.[16] 
Prashanth M et al (2009) found 62.25% [17],Mohan V et 
al (2009) 54.5% [18] Chandel K et al (2016) 55.68% [19] 
of study subjects to have NAFLD. Several studies have 
suggested that age having no association with presence 
of NAFLD in T2DM subjects, similar to our study. [17, 
20, 21,22] Male predominance among subjects with 
NAFLD was also noted in several similar studies. [16, 18, 
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20,23]In our study, subjects with NAFLD had 
significantly higher mean BMI (34.59±4.83) as 
compared to subjects without NAFLD (25.73±2.92) (p 
0.0001). Leite NC et al[20] in a similar study had 
comparable results with mean BMI 27±3.6 in no-
NAFLD group as compared to 31.3 ± 5.4 in NAFLD 
group (p<0.001).Our results were also similar to 
several other Indian studies. [21, 24, 25, 26] The mean waist 
circumference in diabetics with NAFLD was 
significantly higher (91.6 ±4.83 cm) as compared to 
DM (85.6±7.61 cm) group. Leite NC et al (2009)[20] 
Mohan V et al (2009)[18] and Uchil D et al (2009)[23] 
also suggested higher mean waist circumference to be 
significantly associated with NAFLD in diabetics. In 
our study, mean waist hip ratio of T2DM subjects with 
NAFLD was significantly higher than subjects without 
NAFLD (p 0.001). These results suggest that T2DM 
subjects with high waist hip ratio are at a higher risk of 
developing NAFLD. Similar results were found by 
Chandel K et al (2016).[19] In our study, the mean 
systolic BP in subjects with NAFLD was 127.49±23.82 
mmHg as compared to 115.14±18.14 mmHg in 
subjects without NAFLD. This difference was 
significant (p 0.001). The mean diastolic BP in T2DM 
subjects with NAFLD was 79.04±11.37 mmHg as 
compared to 75.42±10.93 mmHg in subjects without 
NAFLD (p 0.024). Mohan V et al (2009) in similar 
study found systolic and diastolic BP to be 
significantly different in NAFLD and non NAFLD 
group in T2DM subjects. SBP (119±17 vs 124±17 
mmHg, p <0.05), DBP (74 ± 11 vs 77 ± 10 mmHg, p 
<0.05)[18]Lv WS et al (2013) [26], Rajender A et al 
(2019)[27] had similar results. In our study, the mean 
HbA1c in diabetic subjects with NAFLD was higher 
(7.07±1.96), as compared to diabetics without NAFLD 
(6.02±1.74) (p 0.021). Viswanathan V et al (2010) 
suggested mean HbA1c to be significantly associated 
with NAFLD (9.7±2.1 vs 8.5±2.1, p 0.01).[24] Similar 
results were seen in studies by Patel H et al (2018)[22] 
Somalwar AM et al (2014) [25] Lv WS et al (2013) [26], 
Prabhakar A et al (2017). [28] Whereas very few studies 
suggested HbA1c not to be significantly associated 
with NAFLD in T2DM subjects. [20,21]In our study, 
total cholesterol (p 0.0426) & triglyceride (p 0.02) 
levels were significantly higher in T2DM subjects with 
NAFLD as compared to T2DM subjects without 
NAFLD. Mean LDL (p 0.054), VLDL (p 0.235) & 
HDL (p 0.113) values were comparable in two study 
groups, suggesting no significant association with 
NAFLD. The results have varied in several studies 
related to different types of lipid fractions. Mohan V et 
al (2008) suggested significantly higher total 
cholesterol and lower HDL in diabetic subjects with 
NAFLD. [18] Patel H et al (2018) suggested total 
cholesterol to be comparable in both groups, but 
triglycerides (p 0.42), LDL(p 0.03) and HDL (p 0.01) 
to be significantly different [22]. Chandel K et al (2016) 
[19],Uchil D et al (2009) [23], Somalwar AM et al (2014) 
[25] suggested total cholesterol, HDL, triglyceride to be 
significantly different in study groups.  Agarwal AK et 
al (2011)[21] Viswanathan V et al (2010)[24] and Lv WS 
et al (2013)[26] also suggested triglycerides to be 
significantly higher in diabetics with NAFLD. In our 
study, 32 (15.09%) subjects had coronary artery 
disease (CAD), including 22.03% of diabetics with 
NAFLD and 9.57% without comorbid NAFLD 
suffered from coronary heart disease. Viswanathan V 
et al (2010) on evaluating 298 diabetics, suggested that 
CAD was significantly higher in subjects with NAFLD 
(11.5% vs 1.4%, p 0.01). [24] Agarwal AK et al (2011) 
on evaluating 124 T2DM subjects suggested that 
NAFLD was significantly correlated with CAD (p 
0.016). [21] Somalwar AM et al (2014) also found a 
significant association between NAFLD and CAD in 
T2DM subjects (70.58% vs 21.11%, p<0.001). [25] 
Prabhakar A et al (2017) in 114 T2DM subjects, used 
binary logistic regression analysis to suggest that 
NAFLD is an independent predictor of CAD (p 0.002) 
[28] 
 
CONCLUSION 
NAFLD in type 2 diabetics is associated with several 
cardiometabolic risk factors and with increased risk of 
coronary artery disease. 
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